Natco Pharma Key Ratios
NSE: NATCOPHARM | BSE: 524816
₹853.80
As on 28-Aug-2026IST
Market cap
₹15,284 Cr
Revenue (TTM)
₹3,485 Cr
P/E Ratio
13.4
P/B Ratio
1.6
Div. Yield
0.6 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -0.53 | -44.68 | -20.73 | 5.55 | 12.91 |
| EBIT | 80.57 | -72.85 | -50.05 | -1.68 | 15.18 |
| Net Profit | -22.92 | -57.04 | -32.59 | 11.97 | 23.82 |
| EPS | -22.92 | -57.04 | -32.59 | 12.32 | 24.26 |
| Book Value | -- | -- | 29.97 | 22.10 | 15.58 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| 38.83 | 28.18 | 24.56 | 44.22 | 39.13 |
| Net Margin
| 34.45 | 25.41 | 26.82 | 39.35 | 33.64 |
| Return on equity
| 22.78 | 16.97 | 12.81 | 27.98 | 25.88 |
| Return on Capital
| 26.21 | 19.97 | -- | 32.85 | 30.08 |
| Return on Assets
| 19.74 | 14.53 | 10.29 | 24.35 | 22.13 |
| Debt to Equity (x)
| -- | -- | 0.01 | 0.04 | 0.06 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
32.85
|
30.08
|
18.06
|
4.86
|
|
Peer Median
|
--
|
14.72
|
18.85
|
11.60
|
--
|
ROE
12.81
Higher than Peers by 1.95
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
12.81
|
27.98
|
25.88
|
15.66
|
4.06
|
|
Peer Median
|
10.86
|
11.67
|
14.92
|
11.46
|
--
|
ROA
10.29
Higher than Peers by 3.55
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
10.29
|
24.35
|
22.13
|
13.29
|
3.43
|
|
Peer Median
|
6.74
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
24.56
Higher than Peers by 11.87
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
24.56
|
44.22
|
39.13
|
27.63
|
6.22
|
|
Peer Median
|
12.69
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
26.82
Higher than Peers by 17.96
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
26.82
|
39.35
|
33.64
|
25.23
|
8.32
|
|
Peer Median
|
8.86
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
44.47
|
36.36
|
30.51
|
14.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-20.73
Lower than Peers by 28.87
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
-20.73
|
10.77
|
47.72
|
39.20
|
-5.23
|
|
Peer Median
|
8.14
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
-50.05
Lower than Peers by 67.29
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
-50.05
|
25.18
|
109.20
|
518.61
|
-75.17
|
|
Peer Median
|
17.24
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
-32.59
Lower than Peers by 49.45
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
-32.59
|
35.66
|
94.09
|
320.76
|
-61.57
|
|
Peer Median
|
16.85
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
-32.59
Lower than Peers by 43.19
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
-32.59
|
35.81
|
97.88
|
320.76
|
-61.44
|
|
Peer Median
|
10.60
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
29.97
|
20.09
|
14.40
|
3.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.01
Lower than Peers by 0.03
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
0.01
|
0.04
|
0.06
|
0.03
|
0.09
|
|
Peer Median
|
0.04
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
0.04
|
0.06
|
0.03
|
0.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.01
Higher than Peers by 1.29
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
3.01
|
5.59
|
4.14
|
4.39
|
3.50
|
|
Peer Median
|
1.72
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
2.47
Higher than Peers by 1.29
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
2.47
|
4.77
|
3.47
|
3.35
|
2.49
|
|
Peer Median
|
1.17
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
24.75
Higher than Peers by 16.89
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
24.75
|
96.87
|
88.16
|
60.44
|
12.42
|
|
Peer Median
|
7.86
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
25.29
Lower than Peers by 0.50
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
25.29
|
28.14
|
29.73
|
31.62
|
31.91
|
|
Peer Median
|
25.79
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
0.35
Lower than Peers by 0.31
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
0.35
|
0.62
|
0.69
|
0.54
|
0.45
|
|
Peer Median
|
0.67
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
93.30
|
86.16
|
93.53
|
85.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
56.17
|
60.81
|
95.32
|
128.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
145.20
|
136.43
|
133.18
|
106.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
--
|
4.27
|
10.54
|
55.67
|
107.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
13.36
Lower than Peers by 26.54
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
13.36
|
7.57
|
12.27
|
14.38
|
81.30
|
|
Peer Median
|
39.90
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
1.64
Lower than Peers by 2.60
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
1.64
|
1.88
|
2.91
|
2.11
|
3.24
|
|
Peer Median
|
4.23
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
0.59
Higher than Peers by 0.48
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
0.59
|
0.75
|
1.00
|
0.98
|
0.59
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
10.72
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
10.72
|
4.85
|
8.75
|
9.52
|
38.67
|
|
Peer Median
|
--
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
15,284
Higher than Peers by 7,672
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Natco Pharma
|
15,284
|
14,279
|
17,032
|
10,287
|
13,821
|
|
Peer Median
|
7,613
|
4,851
|
2,099
|
15,272
|
--
|